2don MSN
Toward experiment-guided AlphaFold: Researchers overcome AI tool's single-conformation limitation
The AI-based program AlphaFold predicts a protein's 3D structure with remarkable accuracy. However, it tends to reduce heterogeneous structures to a single dominant conformation, or shape, and ...
Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF) (FSE: Z62) ("Trillion" or the "Company") is pleased to announce ...
The property owner, Clipper Equity, intends to construct several high-rise apartments that could soon tower over the Metro-North train station next door. Instead of a single structure, Clipper filed ...
Large-scale data-management initiatives sit at the intersection of technical work and organizational change management.
The Beacon Kansas City on MSN
Old, empty office buildings become part of a strategy to reduce KC’s housing shortage
A new tax credit could help fill financial gaps for projects and ease housing shortages in the region. The post Old, empty ...
New Voyage AI capabilities and Search for on-premises and private cloud let enterprises build accurate, compliant AI applications to run anywhere without rewriting their applications and relying on ...
Through NASA's Commercial Smallsat Data Acquisition Program, researchers will gain access to high-SNR GNSS polarimetric radio occultation (PRO) data for weather, precipitation, and Earth system ...
Strategy approves $2B in share and preferred security repurchases, launches a $1.25B BTC monetization program, and retains ...
Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF) (FSE: Z62) ("Trillion" or the "Company") is pleased to announce that a successful ...
NEWEN AI, an industry-tailored AI analytics company, will unveil its beauty-focused AI intelligence platform, VUSSENS, at Cosmoprof North America Las Vegas 2026, the world's largest B2B beauty trade ...
Cameco, Constellation Energy, and Vistra are nuclear-exposed names that could be beneficiaries.
American Diabetes Association’s 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist Publication and presentation detail ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results